RGC
AZN icon

Roberts, Glore & Co’s AstraZeneca AZN Stock Holding History

Roberts, Glore & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,444
Closed -$265K – 219
2025
Q4 		$265K Sell
1,444
-159
-10% -$27.9K 0.07% 186
2025
Q3 		$246K Sell
1,603
-17
-1% -$2.57K 0.07% 191
2025
Q2 		$226K Sell
1,620
-955
-37% -$134K 0.07% 189
2025
Q1 		$378K Hold
2,575
– – 0.12% 145
2024
Q4 		$337K Buy
2,575
+252
+11% +$35.3K 0.1% 155
2024
Q3 		$362K Hold
2,323
– – 0.1% 154
2024
Q2 		$362K Sell
2,323
-67
-3% -$10.1K 0.11% 148
2024
Q1 		$324K Hold
2,390
– – 0.1% 156
2023
Q4 		$322K Hold
2,390
– – 0.1% 151
2023
Q3 		$324K Hold
2,390
– – 0.11% 147
2023
Q2 		$342K Sell
2,390
-115
-5% -$16.9K 0.11% 145
2023
Q1 		$348K Buy
2,505
+38
+2% +$5.11K 0.12% 142
2022
Q4 		$335K Sell
2,467
-186
-7% -$23.3K 0.12% 140
2022
Q3 		$291K Sell
2,653
-271
-9% -$34.4K 0.1% 147
2022
Q2 		$386K Sell
2,924
-122
-4% -$16K 0.13% 135
2022
Q1 		$404K Sell
3,046
-973
-24% -$117K 0.12% 143
2021
Q4 		$468K Buy
4,019
+49
+1% +$5.77K 0.12% 133
2021
Q3 		$477K Buy
+3,970
New +$462K 0.15% 127

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Roberts, Glore & Co's AZN Position: Q1 2026 in Review

Roberts, Glore & Co sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,444 shares — an estimated $265K sold.

Roberts, Glore & Co first reported a position in AZN in Q3 2021 and held it in 18 quarters. The position peaked at $477K in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Roberts, Glore & Co reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 1,444 AstraZeneca shares in Q1 2026, an estimated $265K.
  • Roberts, Glore & Co first reported a position in AstraZeneca in Q3 2021 and held it in 18 quarters.
  • Roberts, Glore & Co's AstraZeneca position peaked at $477K in Q3 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.